What is the outcome of receiving subsequent therapy among patients (pts) with advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC)? Experience from electronic health records (EHR).

被引：0
|
作者：
Le, Dung T.
Janjigian, Yelena Yuriy
Ott, Patrick Alexander
Korytowsky, Beata
Le, Hannah
Trong Kim Le
Zhang, Ying
Maglinte, Gregory
Patel, Dhiren
Shangguan, Tong
Chau, Ian
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Bristol Myers Squibb Co, Lawrenceville, NJ USA
[5] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e16023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16023
引用
收藏
页数：2
相关论文
共 35 条
  • [1] Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: Prevalence and outcome dataTranslating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: prevalence and outcome data.
    Gardeazabal, Itziar
    Hierro, Cinta
    Viaplana, Cristina
    Nuciforo, Paolo
    Vivancos, Ana
    Mercade, Teresa Macarulla
    Garralda, Elena
    Eugenia Semidey, Maria
    Grau Bejar, Juan Francisco
    Dienstmann, Rodrigo
    Landolfi, Stefania
    Alsina, Maria
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] DIRECT AND INDIRECT COSTS ASSOCIATED WITH UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER (GC), GASTROESOPHAGEAL JUNCTION CANCER (GEJC) AND ESOPHAGEAL ADENOCARCINOMA (EAC) FOR PATIENTS AND THEIR CAREGIVERS
    Hall, J.
    Khela, K.
    Bertwistle, D.
    Xiao, H.
    [J]. VALUE IN HEALTH, 2020, 23 : S482 - S483
  • [3] Understanding treatment, utilization, and costs in advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC): Implications for episodic payment models.
    Kelly, Ronan Joseph
    Le, Hannah
    Wu, Sze-Jung
    Laurie, Melissa
    Raval, Amit D.
    Shi, Qian
    Korytowsky, Beata
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Adjuvant chemoradiotherapy in patients (pts) with resectable gastric (GC) or gastroesophageal junction cancer (GEJC): A monoinstitutional experience
    Soini, Barbara
    Pani, Giuseppe
    Caffo, Orazio
    Frisinghelli, Michela
    Veccia, Antonello
    Brugnara, Sonia
    Caldara, Alessia
    DiPasquale, MariaChiara
    Ferro, Antonella
    Mussari, Salvatore
    Murgia, Viviana
    Russo, Lucianna
    Valduga, Francesco
    Tumulo, Salvatore
    Galligioni, Enzo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] TREATMENT PATTERNS AND PERFORMANCE STATUS IN UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER (GC), GASTROESOPHAGEAL JUNCTION CANCER (GEJC) AND ESOPHAGEAL ADENOCARCINOMA (EAC) PATIENTS RECEIVING FIRST LINE (1L) TREATMENT
    Hall, J.
    Khela, K.
    Middleton-Dalby, C.
    Bertwistle, D.
    Xiao, H.
    [J]. VALUE IN HEALTH, 2020, 23 : S485 - S485
  • [6] Comparative effectiveness of nivolumab (NIVO) relative to standard of care (SOC) for advanced/metastatic (adv/met) gastric or gastroesophageal junction cancer (GC/GEJC): A simulated treatment comparison (STC).
    Chau, Ian
    Ayers, Dieter
    Goring, Sarah
    Keeping, Sam
    Goulding, Rebecca
    Cope, Shannon
    Chamot, Eric
    Le, Hannah
    Xu, Yanqing
    Abraham, Pranav
    Korytowsky, Beata
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [7] The humanistic burden reported by patients with unresectable locally advanced or metastatic (adv/met) gastric cancer (GC), gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): An international real-world survey
    Hall, J. P.
    Khela, K.
    Moon, R.
    Middleton-Dalby, C.
    Bertwistle, D.
    Xiao, H.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S918 - S918
  • [8] Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC)
    Chen, Zhendong
    Bai, Yuxian
    Zhang, Tao
    Ying, Jieer
    Lin, Xiaoyan
    Yang, Liu
    Wang, Jun
    Zhang, Juan
    Yu, Fan
    Fei, Cong
    Huang, Ruiqi
    Li, Jin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] The potential drug cost impact of nivolumab (N) in patients with advanced/metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJC) in Canada.
    Virik, Kiran
    Wilson, Robert B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [10] Phase Ib trial of cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with advanced hepatocellular carcinoma (HCC), gastric or gastroesophageal junction cancer (GC/GEJC), or colorectal cancer (CRC).
    Spencer, Kristen Renee
    Ramsingh, Giridharan
    Mohamed, Nehal
    Pal, Sumanta K.
    Rimassa, Lorenza
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
1234